259 related articles for article (PubMed ID: 16309577)
1. Effect of nebivolol on cardiovascular changes associated with a rat model of insulin-resistance.
Renna N; Risler N; Cruzado M; Gonzalez S; Lama C; Miatello RM
Cell Mol Biol (Noisy-le-grand); 2005 Nov; 51(6):531-7. PubMed ID: 16309577
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
[TBL] [Abstract][Full Text] [Related]
3. Effect of chronic aspirin administration on an experimental model of metabolic syndrome.
Renna NF; Vazquez MA; Lama MC; González ES; Miatello RM
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):162-8. PubMed ID: 18785983
[TBL] [Abstract][Full Text] [Related]
4. Dealcoholized red wine reverse vascular remodeling in an experimental model of metabolic syndrome: role of NAD(P)H oxidase and eNOS activity.
Vazquez-Prieto MA; Renna NF; Lembo C; Diez ER; Miatello RM
Food Funct; 2010 Oct; 1(1):124-9. PubMed ID: 21776463
[TBL] [Abstract][Full Text] [Related]
5. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
Toblli JE; Cao G; Casas G; Mazza ON
Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
[TBL] [Abstract][Full Text] [Related]
7. Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure.
Gschwend S; Haug MB; Nierhaus M; Schulz A; Vetter R; Kossmehl P; Orzechowski HD; Scholze J; Rothermund L; Kreutz R
Life Sci; 2009 Sep; 85(11-12):431-7. PubMed ID: 19635487
[TBL] [Abstract][Full Text] [Related]
8. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction.
Pires MJ; Rodríguez-Peña AB; Arévalo M; Cenador B; Evangelista S; Esteller A; Sánchez-Rodríguez A; Colaço A; López-Novoa JM
J Hypertens; 2007 Dec; 25(12):2486-96. PubMed ID: 17984671
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
10. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
11. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats.
Miatello R; Vázquez M; Renna N; Cruzado M; Zumino AP; Risler N
Am J Hypertens; 2005 Jun; 18(6):864-70. PubMed ID: 15925749
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
13. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation.
Kubli S; Feihl F; Waeber B
Clin Pharmacol Ther; 2001 Apr; 69(4):238-44. PubMed ID: 11309552
[TBL] [Abstract][Full Text] [Related]
14. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
15. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
Sacco G; Evangelista S; Criscuoli M; Goso C; Bigioni M; Binaschi M; Manzini S; Maggi CA
Eur J Pharmacol; 2005 Mar; 511(2-3):167-74. PubMed ID: 15792785
[TBL] [Abstract][Full Text] [Related]
16. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of losartan reverses cardiovascular changes in hypertensive fructose-fed rats.
Miatello R; Risler N; Castro C; Cruzado M; González S; Zumino AP
Cell Mol Biol (Noisy-le-grand); 2003 Sep; 49(6):945-52. PubMed ID: 14656052
[TBL] [Abstract][Full Text] [Related]
18. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
Ignarro LJ
Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
[TBL] [Abstract][Full Text] [Related]
19. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension.
Predel HG; Mainka W; Schillings W; Knigge H; Montiel J; Fallois J; Agrawal R; Schramm T; Graf C; Giannetti BM; Bjarnason-Wehrens B; Prinz U; Rost RE
J Hum Hypertens; 2001 Oct; 15(10):715-21. PubMed ID: 11607802
[TBL] [Abstract][Full Text] [Related]
20. ENOS is not activated by nebivolol in human failing myocardium.
Brixius K; Song Q; Malick A; Boelck B; Addicks K; Bloch W; Mehlhorn U; Schwinger RH
Life Sci; 2006 Aug; 79(13):1234-41. PubMed ID: 16716362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
